Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue		$ 1,010	$ 446
Operating expenses:
Cost of revenue		1,744	1,346
Sales and marketing		4,311	4,539
General and administrative		6,678	10,407
Amortization of acquired intangible assets		372	505
Research and development		1,941	4,050
Total operating expenses		15,046	20,847
Operating loss		(14,036)	(20,401)
Other income (expense):
Interest income		72	121
Interest expense		(16)	(183)
Change in fair value - Senior Secured Convertible Notes		(2,163)	(1,040)
Loss on issue and offering costs - Senior Secured Convertible Note			(1,186)
Debt extinguishments loss - Senior Secured Convertible Notes		(369)	(525)
Debt modification expense		(2,000)
Gain on sale of intellectual property			1,000
Other income (expense), net		(4,476)	(1,813)
Loss before provision for income tax		(18,512)	(22,214)
Provision for income taxes
Net loss before noncontrolling interests		(18,512)	(22,214)
Net loss attributable to the noncontrolling interests		3,300	4,283
Net loss attributable to PAVmed Inc.		(15,212)	(17,931)
Less: Series B Convertible Preferred Stock dividends earned		(80)	(74)
Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests		(7,496)
Net loss attributable to PAVmed Inc. common stockholders		$ (22,788)	$ (18,005)
Per share information:
Net loss per share attributable to PAVmed Inc. common stockholders - basic	[1]	$ (2.62)	$ (2.78)
Net loss per share attributable to PAVmed Inc. common stockholders - diluted	[1]	$ (2.62)	$ (2.78)
Weighted average common shares outstanding, basic		8,694,904	6,473,010
Weighted average common shares outstanding, diluted		8,694,904	6,473,010

[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.